Abstract
BackgroundAnti-PD1/PD-L1 immunotherapy is the standard of care for metastatic NSCLC but many tumors develop resistance. We hypothesize based on existing preclinical and clinical data that combining a T-cell agonist such...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have